Last reviewed · How we verify

Orotracheal Lidocaine Oral Spray application

Abant Izzet Baysal University · FDA-approved active Small molecule

Lidocaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

Lidocaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and conduction of nerve impulses to produce local anesthesia. Used for Topical anesthesia of the oropharynx prior to intubation and other oropharyngeal procedures.

At a glance

Generic nameOrotracheal Lidocaine Oral Spray application
SponsorAbant Izzet Baysal University
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia / Pain Management
PhaseFDA-approved

Mechanism of action

Lidocaine works by reversibly inhibiting sodium influx through voltage-gated sodium channels in the neuronal membrane, which stabilizes the membrane and raises the threshold for electrical excitability. When applied topically as an oral spray, it anesthetizes the oropharyngeal mucosa and surrounding tissues, providing rapid onset of local anesthesia. This effect is useful for reducing discomfort during intubation procedures and other oropharyngeal interventions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results